Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01634685 · ClinicalTrials.gov registry record · Phase 1
A Phase I Study of Bavituximab, Capecitabine, and Radiation for the Treatment of Rectal Adenocarcinoma
A Phase 1 study, sponsored by University of Texas Southwestern Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT01634685 is a Phase 1 study that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 15 participants.
The verdict
NCT01634685, a Phase 1 study, has completed, sponsored by University of Texas Southwestern Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
This is a phase I study incorporating bavituximab into the care of patients with rectal adenocarcinoma simultaneously treated with capecitabine and radiation therapy. There is no reference therapy as we are trying to identify the MTD of bavituximab in this combination.
Interventions
- DRUG Capecitabine
- RADIATION Radiation
- DRUG Bavituximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2012-08-08 |
| Est. Completion | 2017-10-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01634685
The ClinicalTrials.gov registry entry for NCT01634685 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Capecitabine is the first listed.
NCT01634685 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01634685 about?
NCT01634685 is a clinical study titled "A Phase I Study of Bavituximab, Capecitabine, and Radiation for the Treatment of Rectal Adenocarcinoma". This is a phase I study incorporating bavituximab into the care of patients with rectal adenocarcinoma simultaneously treated with capecitabine and radiation therapy. There is no reference therapy as we are trying to identify the MTD of bavituximab in this combination.
What is the current status of trial NCT01634685?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2012-08-08. Estimated completion is 2017-10-06.
What interventions are being tested in trial NCT01634685?
The interventions under investigation include: Capecitabine (DRUG), Radiation (RADIATION), Bavituximab (DRUG).
Who is sponsoring clinical trial NCT01634685?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.